GlassScriptPhysician profile
Natalie Miller
NPI 1235578477
$4,960.70
in general payments reported to CMS, 2019-2025
23 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $350 · 2023: $825 · 2024: $1,743 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.27 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,234.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,134.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $405.66 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $304.26 | 2024-2025 | Tremfya |
| Genzyme Corporation | $285.10 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $230.86 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $202.94 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $150.59 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $120.00 | 2025 | Nemluvio |
| Amgen INC. | $106.16 | 2021-2025 | Otezla |
| Pfizer INC. | $96.56 | 2024-2025 | |
| Lilly USA, LLC | $96.37 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $94.10 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $90.78 | 2021-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $67.77 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $61.45 | 2022-2025 | Affinity |
| Almirall LLC | $59.65 | 2021-2025 | Klisyri |
| Sun Pharmaceutical Industries INC. | $53.26 | 2022-2025 | |
| Organon LLC | $51.68 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.01 | 2021-2025 | Jublia |
| Journey Medical Corporation | $38.18 | 2025 | |
| Dermira, INC. | $21.23 | 2021 | |
| Biofrontera INC. | $9.37 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.